+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer



The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer



Oncology 55(1): 33-38



The relationship between c-erbB-2 serum positivity and prognosis was evaluated in 80 patients with metastatic breast cancer. Using 120 fmol/ml as a cutoff level, elevated concentrations were found in 31 patients (38.8%) at the time of detection of metastases. Menopausal status, steroid receptor status, site of recurrence, initial tumor size, initial degree of nodal involvement as well as relapse-free interval were unrelated to c-erbB-2 serum positivity. In addition, no association could be found between adjuvant chemotherapy and positive c-erbB-2 concentrations. Patients with elevated c-erbB-2 levels showed a lower response rate (including complete remission, partial remission, no change) to first-line therapy than those with normal levels (29 vs. 59%, p < 0.01). The median survival time after relapse was 12 months (CI: 3-22 months) for the c-erbB-2-negative patients and only 6 months (CI: 3-8 months) for the c-erbB-2-positive group (p < 0.01). In the multivariate analysis, while c-erbB-2 levels at the time of primary surgery had no significant impact on survival in metastatic breast cancer, serum c-erbB-2 turned out to be the strongest factor for predicting survival after relapse.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009611159

Download citation: RISBibTeXText

PMID: 9428373


Related references

The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer. Oncology 55(1): 33-38, 1998

Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Research & Treatment 40(3): 251-255, 1996

Prognostic significance of overexpression of serum c-erbB-2 protein in primary breast cancer patients. Breast 10(Supplement 1): S20, 2001

Prognostic significance of overexpression of cytosol and serum c-erbB-2 protein in primary breast cancer patients. Breast Cancer Research & Treatment 57(1): 101, 1999

Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Research 17(2b): 1319-1330, 1997

Prognostic significance of serum C-erbB-2 levels in hormonally treated advanced breast cancer patients. Anticancer Research 19(6D): 5693-5694, 1999

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology 8(1): 103-112, 1990

Courses of serum C-ERBB-2 and CA15-3 protein levels in metastatic breast cancer. Annals of Hematology 77(SUPPL 2): S115, 1998

Serum c-erbB-2 protein is an independent prognostic factor in operable breast cancer patients. Clinical Chemistry 48(6 Supplement): A14, 2002

Clinical significance of serum c-erbB-2 protein in patients with primary breast cancer. Oncology Reports 4(2): 349-352, 1997

Prognostic significance of serum phosphohexose isomerase in metastatic breast cancer. Medizinische Klinik 82(11): 385-391, 1987

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Research and Treatment 98(3): 241-248, 2006

Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Research 24(3b): 1987-1992, 2004

Circulating C-ErbB-2 as a prognostic marker in patients with metastatic breast cancer. Tumor Biology 18(SUPPL 1): 93, 1997

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis 36(2): 243-248, 2015